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Background: Manuka honey originates from the manuka tree (Leptospermum scoparium) and its antimicrobial
effect has been attributed to a property referred to as Unique Manuka Factor that is absent in other types of honey.
Antibacterial activity of Manuka honey has been documented for several bacterial pathogens, however there is no
information on Clostridium difficile, an important nosocomial pathogen. In this study we investigated susceptibility
of C. difficile to Manuka honey and whether the activity is bactericidal or bacteriostatic.
Methods: Three C. difficile strains were subjected to the broth dilution method to determine minimum inhibitory
concentrations (MIC) and minimum bactericidal concentrations (MBC) for Manuka honey. The agar well diffusion
method was also used to investigate sensitivity of the C. difficile strains to Manuka honey.
Results: The MIC values of the three C. difficile strains were the same (6.25% v/v). Similarly, MBC values of the three
C. difficile strains were the same (6.25% v/v). The activity of Manuka honey against all three C. difficile strains was
bactericidal. A dose–response relationship was observed between the concentrations of Manuka honey and zones
of inhibition formed by the C. difficile strains, in which increasing concentrations of Manuka honey resulted in
increasing size of zone of inhibition formed. Maximum zone of inhibition was observed at 50% (v/v) Manuka honey
and the growth inhibition persisted over 7 days.
Conclusion: C. difficile is appreciably susceptible to Manuka honey and this may offer an effective way of treating
infections caused by the organism.Background
Clostridium difficile is a Gram positive anaerobic spore-
forming bacillus, and is part of the normal gut flora in less
than 5% of humans [1]. The organism is associated with se-
vere infections including diarrhea, pseudomembranous col-
itis, toxic megacolon, perforation of the colon, and in some
cases, sepsis [2]. C. difficile is an important nosocomial
agent and currently accounts for 30-50% of hospital ac-
quired infections with serious economic burden for many
countries [3,4]. A number of risk factors for C. difficile as-
sociated diseases, including the use of certain antibiotics,
particularly fluoroquinolones, have been identified [4-6]. In
the pathogenesis of diarrhoea caused by the organism,
these antibiotics suppress normal flora of the gut and allow
the proliferation of C. difficile with the production of two
toxins (TcdA and TcdB) which cause the disease [6,7].* Correspondence: hammondes@yahoo.com
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distribution, and reproduction in any mediumAntibiotic resistance is a major public health threat es-
pecially, with important pathogens such as C. difficile [8].
The problem is associated with overuse and misuse of an-
tibiotics that provide selective pressure favouring the
emergence of resistant strains [9,10]. The escalating trend
of microbial resistance to essential antibiotics, especially
multidrug resistance underscores the need for evaluating
alternative potential therapeutic agents with antibacterial
properties. The use of honey for treating microbial infec-
tions dates back to ancient times, though antimicrobial
properties of Manuka honey was discovered recently
[11-16]. Manuka honey originates from the manuka tree
(Leptospermum scoparium) and its antimicrobial effect
has been attributed to a property referred to as Unique
Manuka Factor that is absent in other types of honey [17].
Lately, studies have shown that the active ingredient in
Manuka honey is Methylglyoxal [18,19], and this com-
pound is known to have synergistic effect with some anti-
biotics such as piperacillin [20]. To date there are
numerous studies that have demonstrated the therapeuticed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ity against a wide range of pathogenic bacteria [21-23].
Consequently, Manuka honey has been recommended for
the treatment of ailments such as leg ulcers, piloni-
dal sinus disease and gastrointestinal infection [24,25].
Though susceptibility of several bacterial pathogens to
Manuka honey has been investigated, there is no data on
C. difficile, and hence the current study investigated the
antibacterial effect of Manuka honey against the organism.
In this study, we provide evidence of the susceptibility of




Three C. difficile strains were used in this study. The
three strains were labeled Strains A, B and C. Strain A
was the ATCC 9689 strain (PCR-ribotype X). Strains B
and C were clinical isolates of PCR ribotypes 027 and
106 respectively. The strains were provided by the An-
aerobe Reference Laboratory at the University of Wales
Hospital, and maintained at the Department of Micro-
biology, University of Wales Institute Cardiff (UWIC).
The C. difficile strains were grown/stored in Robertson’s
Cook meat medium (Oxoid, Cambridge, UK) and a pur-
ity test [26] was performed on each strain before it was
used in the study.
Manuka honey
Woundcare™ 18+ Active Manuka honey (potency equiva-
lent of greater than 18% v/v phenol) with non-peroxide
antibacterial activity from Comvita UK was used in this
study.
Determination of MIC/MBC of Manuka honey for C. difficile
strains by broth dilution
Minimum inhibitory concentrations (MIC) refers to the
lowest concentration of an antimicrobial that will inhibit
the visible growth of a microorganism while minimum
bactericidal concentration (MBC) refers to lowest con-
centration of an antimicrobial that will kill the micro-
organism [26,27]. MICs of Manuka honey for the C.
difficile strains were determined using the broth dilution
method of susceptibility testing described by European
Committee on Antimicrobial Susceptibility Testing [18].
A stock solution of 50% (v/v) Manuka honey was pre-
pared by dissolving 12.5 g honey in 25ml sterile deionised
water. Four millilitres of this solution was pipetted into
an empty test tube and labelled 1. Two millilitres of
prereduced thioglycolate broth (Oxoid, Cambridge, UK)
was pipetted into nine other test tubes. Subsequently
2 ml honey solution from test tube 1 was transferred to
test tube 2 containing thioglycolate to prepare a two-
fold serial dilution. The tubes were inoculated with100 μl (105 cfu) of an overnight culture of a C. difficile
strain in an anaerobic cabinet (Don Whitley Scientific/
MACS, UK) at 37°C for 48 hours. Positive and negative
controls were set with 2 mls of the thioglycolate broth
(without honey solution) containing 100 μl (105 cfu) in-
oculums and 2 ml of the thioglycolate broth without in-
oculum respectively. After 48 hours incubation, each
tube was examined for the presence and absence of tur-
bidity to indicate growth of the microorganism. The first
broth or lowest concentration of honey that inhibited
growth of the microorganism was designated the MIC
[26,27]. The results were scored as ‘bacterial growth’ (+)
and ‘no bacterial growth’ (−). This test was done in trip-
licate to ensure reproducibility of results.
To determine the MBC, 10 μl of a sample from the
MIC broth that showed no turbidity was streaked onto
drug-free medium, prereduced fastidious anaerobic agar
plates (Oxoid, Cambridge, UK) in an anaerobic cabinet
and incubated at 37°C for 24 hours. MBC was defined as
the first dilution at which no growth was examined [27].
Any colonies that developed were scored as ‘bacterial
growth’ (+) and ‘no bacterial growth’ (−).
Evaluation of sensitivity of C. difficile strains to Manuka
honey by agar diffusion
Sensitivity of the C. difficile strains to Manuka honey was
determined using the agar diffusion method of suscepti-
bility testing described by European Committee on Anti-
microbial Susceptibility Testing [28]. An overnight culture
of the test strain in Robertson’s Cook Meat medium
(Oxoid, Cambridge, UK) was used to prepare a lawn on a
prereduced Fastidious anaerobic agar plate by uniformly
swabbing the surface of the agar with a sterile swab stick
dipped into the broth culture. Wells were then cut in each
agar plate aseptically using a sterile cork borer (8 mm in
diameter). These wells were subsequently filled with
350 μl of 50% (v/v) honey solution (5 g honey dissolved in
double strength iso-sensitest broth and made up to the
10 ml mark) and incubated at 37°C for 7 days in an anaer-
obic cabinet. The negative control used in this experiment
consisted of 350 μl double strength iso-sensitest broth
(Oxoid, Cambridge, UK) without honey. The zones of
inhibition were measured every 24 hours over a period
of 7 days using digital vernier callipers (Swiss Precision/
Digimax) and compared to the readings of the control
plate. Incubated plates showing zones of inhibition were
also monitored from days 1 to 7 for the appearance of
C. difficile colonies in the zone of inhibition. For each C.
difficile strain, the sensitivity experiments were per-
formed for honey solutions of 40%, 30%, 20% and 10%
(v/v) in triplicates. However, the plates were incubated
up to 48 hours (2 days), as the inhibition zones of the
50% v/v Manuka honey did not change after 48 hours of
incubation.






Mean zone of inhibition (mm) ± SD
Strain A (ATCC 9689) Strain B Strain C
1-7 0 0 0 0
1-7 10 0 0 0
1-7 20 0 0 0
1 30 0 9.1 ± 0.12 0
2 30 8.4 ± 0.11 9.3 ± 0.29 0
1 40 9.5 ± 0.31 10.2 ± 0.33 10.2 ± 0.27
2 40 10.2 ± 0.4 10.4 ± 0.20 10.2 ± 0.24
1 50 13.6 ± 0.78 13.9 ± 0.32 14.0 ± 0.24
2 50 14.3 ± 0.50 14.5 ± 0.22 14.2 ± 0.23
3 50 13.9 ± 0.50 14.0 ± 0.28 13.9 ± 0.26
4 50 14.2 ± 0.63 14.1 ± 0.42 14.2 ± 0.28
7 50 14.5 ± 0.52 14.5 ± 0.41 14.7 ± 0.45
± SD (standard deviation).
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The MIC and MBC of Manuka honey for the three C. dif-
ficile strains investigated is shown in Table 1. The MIC
values of the three C. difficile strains were the same (6.25%
v/v). Similarly, MBC values of the three C. difficile strains
were the same (6.25% v/v). The MBC/MIC ratio for each
of the strains was 1.0. MIC/MBC are used in confirming
susceptibility test results, especially for serious infections,
and are also important for monitoring the activity of new
antimicrobial agents [27,29]. Though there is hardly any
data on antibacterial effect of Manuka honey against C.
difficile, MIC and MBC values of several bacterial agents
in relation to Manuka honey have been determined and
can be used for comparison with our data. Cooper et al.
[30] reported that the MIC of 58 isolates of Staphylococcus
aureus from infected wound was 3 - 4% (v/v). In another
report, Cooper and Molan [31] determined the MIC of
Manuka honey for 20 strains of Pseudomonas aeruginosa
isolated from infected wounds to be between 5.5% (v/v)
and 8.7% (v/v). Furthermore, Cooper et al. [32] tested the
sensitivity of 17 strains of P. aeruginosa isolated from
infected burns with Manuka honey (with median level of
activity) and observed MICs below 10% (v/v) for all the
test strains. Wilkinson and Cavanagh [33] reported that
Manuka honey was effective against many organisms in-
cluding S. aureus (MIC100 = 1.8), E. coli (MIC100 = 3.7),
Salmonella typhimurium (MIC100 = 6) and Proteus
mirabilis (MIC100 = 7.3) % (v/v). The MIC values observed
for the C. difficile strains in this study thus appear to be
similar to MIC values that have been reported for some
other bacteria particularly, P. aeruginosa. It is known that
bacteriostatic antimicrobial agents have an MBC/MIC ra-
tio greater than or equal to 16 for a given bacterium, while
for bactericidal antimicrobial agents the MBC/MIC ratio
is less than or equal to 4 [34]. The MBC/MIC ratios for
the different C. difficile strains in this study (Table 1) sug-
gest that Manuka honey exhibits a bactericidal mode of
action against C. difficile.
Further evidence of the efficacy of Manuka honey
against the C. difficile test strains was determined by meas-
uring zone of inhibition in agar well diffusion experiments
(Table 2/Figure 1). It was observed that 10 and 20% (v/v)
Manuka honey concentrations did not show any visible
measureable zone of inhibition indicating that at these
concentrations, the organisms were not sensitive to theTable 1 Minimum inhibitory concentrations and minimum
bactericidal concentrations of Manuka honey for different
C. difficile strains
C. difficile strain PCR ribotype MIC MBC MBC/MIC ratio
Strain A (ATCC 9689) PCR ribotype X 6.25 6.25 1
Strain B PCR ribotype 027 6.25 6.25 1
Strain C PCR ribotype 106 6.25 6.25 1effect of Manuka honey. At 30% (v/v) Manuka honey con-
centration, there was no visible effect on Strain C, how-
ever zones of inhibition were observed for Strain A
(ATCC 9689) and Strain B, with the former being more
sensitive. At concentrations of 40 and 50% (v/v), all the
three C. difficile test strains showed considerable sensitiv-
ity to Manuka honey and produced comparable zones of
inhibition. Generally, in this study, increasing Manuka
honey concentrations correlated with increase in the sizeFigure 1 Picture showing inhibition zones after 7 days
incubation of Clostridium difficile in the presence of 50% v/v
Manuka honey.
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bacterial properties such as Unique Manuka Factor
present in Manuka honey as well as its osmolarity
which increases with increasing honey concentration
[17]. Generally, the test strains were inhibited at lower
Manuka honey concentrations in liquid medium
(Table 1) than on agar well diffusion plates (Table 2)
which may be due to the Manuka honey solution be-
ing able to diffuse more uniformly, efficiently and
faster in the former.
Conclusion
In this study, we provide the first data on antibacterial
effect of Manuka honey against C. difficile. Our data
demonstrates susceptibility of the C. difficile strains to
Manuka honey with MIC of 6.25% (v/v) and MBC of
6.25% (v/v). Manuka honey exhibits a bactericidal action
against C. difficile, a feature which is likely to make
Manuka honey highly attractive in the treatment of bac-
terial infections. Our data adds to the body of research
evidence in support of the broad antibacterial spectrum
of Manuka honey.
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